The receptor tyrosine kinase Mer promotes multiple myeloma progression and osteolytic bone disease

被引：0

作者：

Engelmann, J. ^{[1
,2
]}

Ben Batalla, I. ^{[1
,2
]}

Taipaleenmaeki, H. ^{[3
]}

Riecken, K. ^{[4
]}

Gensch, V. ^{[1
,2
]}

Paesler, S. ^{[1
,2
]}

Berenbrok, N. ^{[1
,2
]}

Vargas, M. E. ^{[1
,2
]}

Waizenegger, J. ^{[2
]}

Fehse, B. ^{[4
]}

Pantel, K. ^{[2
]}

Darwish, I. ^{[5
]}

Bhamidipati, S. ^{[5
]}

Masuda, E. ^{[5
]}

Bokemeyer, C. ^{[1
]}

Hesse, E. ^{[3
]}

Loges, S. ^{[1
,2
]}

机构：

[1] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin 2, Abt Pneumol, Onkol,Hamatol,Knochenmarktransplantat, Hamburg, Germany

[2] Univ Klinikum Hamburg Eppendorf, Inst Tumorbiol, Hamburg, Germany

[3] Univ Klinikum Hamburg Eppendorf, Expt Unfallchirurg, Heisenberg Arbeitsgrp, Hamburg, Germany

[4] Univ Klinikum Hamburg Eppendorf, Interdisziplinare Klin & Poliklin Stammzelltransp, Hamburg, Germany

[5] Rigel Pharmaceut Inc, San Francisco, CA USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P708

引用

页码：190 / 190

页数：1

共 50 条

[21] Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease
E Terpos
J Berenson
R J Cook
A Lipton
R E Coleman
Leukemia, 2010, 24 : 1043 - 1049
[22] Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease
Terpos, E.
Berenson, J.
Cook, R. J.
Lipton, A.
Coleman, R. E.
LEUKEMIA, 2010, 24 (05) : 1043 - 1049
[23] LIGHT/TNFSF14 INVOLVEMENT IN MULTIPLE MYELOMA-OSTEOLYTIC BONE DISEASE
Rizzi, R.
Brunetti, G.
Oranger, A.
Gigante, I.
Mongelli, T.
Gagliardi, V. P.
Mestice, A.
Curci, P.
Colucci, S.
Specchia, G.
Grano, M.
HAEMATOLOGICA, 2015, 100 : 157 - 157
[24] A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma
Papanota, Aristea-Maria
Tsiakanikas, Panagiotis
Kontos, Christos K.
Malandrakis, Panagiotis
Liacos, Christine-Ivy
Ntanasis-Stathopoulos, Ioannis
Kanellias, Nikolaos
Gavriatopoulou, Maria
Kastritis, Efstathios
Avgeris, Margaritis
Dimopoulos, Meletios-Athanasios
Scorilas, Andreas
Terpos, Evangelos
CANCERS, 2021, 13 (15)
[25] 18F-FDG-PET/CT and Osteolytic Bone Disease in Multiple Myeloma
Ostergaard, Brian
Mortensen, Julie R.
Nielsen, Anne L.
Asmussen, Jon T.
Gerke, Oke
Plesner, Torben
Hoilund-Carlsen, Poul Flemming
Abildgaard, Niels
BLOOD, 2016, 128 (22)
[26] Deregulation of the bone marrow stromal compartment occurs early in multiple myeloma and precedes osteolytic bone disease
Kassen, D.
Rabin, N.
Lath, D.
Croucher, P.
Yong, K.
BONE, 2011, 48 : S253 - S254
[27] GENE EXPRESSIONS IN WHOLE BONE MARROW SAMPLES AND ASSOCIATION WITH OSTEOLYTIC BONE DISEASE IN MULTIPLE MYELOMA PATIENTS
Kristensen, I.
Haaber, J.
Petersen, M.
Ditzel, H.
Abildgaard, N.
HAEMATOLOGICA, 2012, 97 : 590 - 590
[28] Pharmacotherapy with Pamidronate Disodium of Osteolytic Bone Metastases of Breast Cancer, Osteolytic Lesions of Multiple Myeloma, and Paget's Disease
Hoff, Ana O.
Novis, Yana
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 953 - 962
[29] Bruton's Tyrosine Kinase (BTK) Is Indispensable for Myeloma Cell Migration towards SDF-1 and Induction of Osteoclastogenesis and Osteolytic Bone Disease
Bam, Rakesh
Pennisi, Angela
Li, Xin
Khan, Sharmin
Wang, Yuping
Ling, Wen
Barlogie, Bart
Shaughnessy, John, Jr.
Yaccoby, Shmuel
BLOOD, 2010, 116 (21) : 200 - 201
[30] Genetically engineered osteoprotegerin for multiple myeloma osteolytic bone damage
Higgs, Jerome T.
Jarboe, John
Ponnazhagan, Selverangan
CANCER RESEARCH, 2012, 72

← 1 2 3 4 5 →